Patents by Inventor Yingjun Zhang

Yingjun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180334460
    Abstract: The invention relates to octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof. Compounds and pharmaceutical compositions comprising the compounds provided herein are used for antagonizing orexin receptors. The invention also relates to processes for preparing the compounds and pharmaceutical compositions, and uses thereof in treating or preventing a disease related to orexin receptors.
    Type: Application
    Filed: November 23, 2016
    Publication date: November 22, 2018
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Yingjun ZHANG, Chuanfei JIN, Ji ZHANG
  • Publication number: 20180298019
    Abstract: The invention relates to a salt, a hydrate or a crystalline form of an EGFR inhibitor, and use thereof. Specifically it relates to 4-[(3-chloro-4-fluorophenyl) amino]-7-methoxy-6-[3-[(1R,6S)-2,5-dioxa-8-azabicyclo [4.3.0] nonan-8-yl] propoxy]quinazoline dimethanesulfonate, hydrate and a crystalline form thereof; the invention also relates to a preparation method of the crystalline form disclosed herein, a pharmaceutical composition containing the crystalline form, and uses thereof for treating proliferative disorders.
    Type: Application
    Filed: October 18, 2016
    Publication date: October 18, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Bing LIU, Weihong ZHANG, Yingjun ZHANG
  • Patent number: 10098889
    Abstract: This invention relates to L-tartaric acid complexes, acid addition salts, base addition salts of the compound named (S)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl) morpholine-3-carboxylic acid or tautomer thereof and pharmaceutical compositions thereof, and further relates to use of the compounds or the pharmaceutical compositions in the manufacture of a medicament, especially for use in preventing, managing, treating or lessening a HBV infection. The complex, acid addition salt or base addition salt of the present invention is crystalline form, substantially crystalline form, polymorphism, amorphism, hydrate or solvate.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: October 16, 2018
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qingyun Ren, Liang Chen, Xinchang Liu, Jinsheng Liang, Chenliang Wu, Zhifu Zou, Guanghua Yan, Desheng Huangfu, Siegfried Goldmann, Yingjun Zhang
  • Publication number: 20180263991
    Abstract: This invention relates to L-tartaric acid complexes, acid addition salts, base addition salts of the compound named (S)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl) methyl) morpholine-3-carboxylic acid or tautomer thereof and pharmaceutical compositions thereof, and further relates to use of the compounds or the pharmaceutical compositions in the manufacture of a medicament, especially for use in preventing, managing, treating or lessening a HBV infection. The complex, acid addition salt or base addition salt of the present invention is crystalline form, substantially crystalline form, polymorphism, amorphism, hydrate or solvate.
    Type: Application
    Filed: February 1, 2016
    Publication date: September 20, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD
    Inventors: Qingyun Ren, Liang CHEN, Xinchang LIU, Jinsheng LIANG, Chenliang WU, Zhifu ZOU, Guanghua YAN, Desheng HUANGFU, Siegfried GOLDMANN, Yingjun ZHANG
  • Patent number: 10065934
    Abstract: Provided herein are novel substituted urea derivatives, and pharmaceutical compositions thereof. Also provided herein are uses of the compounds or pharmaceutical compositions thereof for preventing, managing, treating or lessening a proliferative disease, and modulating the activity of protein kinase.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: September 4, 2018
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Changchung Cheng, Yingjun Zhang, Bing Liu, Bohua Long, Yu Chen, Zhixin Cheng
  • Patent number: 10065928
    Abstract: Provided herein are a quinolinone compound, pharmaceutical composition thereof, and use of the compound or the pharmaceutical composition in drug preparation, the drug being used to prevent, manage, treat or relieve diseases related to HIF and/or EPO of a patient, including anemia, vascular disease, myocardial ischemia, dysmetabolism, or for wound healing.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: September 4, 2018
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yinglin Zuo, Xiaojun Wang, Yingjun Zhang, Liang Wen, Shoutao Wu, Xiaofeng Yuan
  • Publication number: 20180230102
    Abstract: Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.
    Type: Application
    Filed: August 31, 2016
    Publication date: August 16, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinye YANG, Changwei HUANG, Facheng MA, Ji ZHANG, Xiaojun WANG, Yingjun ZHANG
  • Publication number: 20180230138
    Abstract: The invention relates to capthepsin K inhibitors and uses thereof, specifically relates to a class of compounds having the formula (I) which are used for treating or preventing cathepsin dependent diseases or conditions, specifically, wherein the cathepsin is capthepsin K. The compounds and compositions thereof can be used as bone resorption inhibitors for the treatment of associated diseases.
    Type: Application
    Filed: August 26, 2016
    Publication date: August 16, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xiaojun WANG, Pingjian ZHOU, Chuanwen YANG, Changwei HUANG, Shaohui XIONG, Yingjun ZHANG, Jiancun ZHANG
  • Publication number: 20180215737
    Abstract: The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses; wherein the compounds or pharmaceutical compositions disclosed herein can be used for antagonizing the orexin receptor. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing neurological and psychiatric disorders and diseases of the central nervous system in mammals, especially in humans.
    Type: Application
    Filed: July 14, 2016
    Publication date: August 2, 2018
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Yingjun ZHANG, Chuanfei JIN, Jinheng GAO, Ji ZHANG
  • Publication number: 20180179188
    Abstract: The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted piperazine compounds and pharmaceutical compositions comprising the compounds disclosed herein can be used for inhibiting 5-hydroxytryptamine reuptake and/or stimulating 5-HT1A receptors. The invention also relates to processes for preparing these compounds and pharmaceutical compositions, and their uses in the treatment of a central nervous system dysfunction.
    Type: Application
    Filed: June 2, 2016
    Publication date: June 28, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Chuanfei JIN, Haiping LIANG, Chao YI, Ji ZHANG
  • Patent number: 9974785
    Abstract: Provided herein are aromatic heterocyclic derivatives or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof used for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: May 22, 2018
    Assignee: Sunshine Lake Pharma Co., Ltd.
    Inventors: Yingjun Zhang, Chuanfei Jin, Wenhe Zhong, Kangzhi Chen, Li Gao, Runzhi Liu, Ji Zhang
  • Patent number: 9951010
    Abstract: The compounds of Formula (I) which can be used as CRTH2 receptor antagonists are provided. The compounds of Formula (I) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin D2 (PGD2) at the CRTH2 receptor.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 24, 2018
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Tianzhu Yu, Bing Liu, Xiangyu Zhang, Shiguo Zhang, Changchung Cheng, Jiancun Zhang
  • Patent number: 9902712
    Abstract: The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: February 27, 2018
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiancun Zhang, Xiaojun Wang, Yingjun Zhang, Runfeng Lin, Yi Yu, Liang Chen, Jihua Lin
  • Publication number: 20180030003
    Abstract: The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.
    Type: Application
    Filed: February 5, 2016
    Publication date: February 1, 2018
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Xiaojun WANG, Xinye YANG, Shengqiang PAN, Rui GUO, Junwen WU, Yingjun ZHANG, Changchung CHENG
  • Patent number: 9840482
    Abstract: Provided herein are sulfonamide derivatives or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: December 12, 2017
    Assignee: Sunshine Lake Pharma Co., Ltd.
    Inventors: Yingjun Zhang, Chuanfei Jin, Wenhe Zhong, Hongpeng Xie, Ji Zhang
  • Patent number: 9828373
    Abstract: The invention provides compounds as CDK small-molecule inhibitors and uses thereof, the compounds can be used for treating inflammation and cell proliferation diseases. The novel compound of the invention is a powerful cyclin-dependent kinase 4 (CDK 4) or cyclin-dependent kinase-6 (CDK 6) inhibitor.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 28, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Bing Liu, Yingjun Zhang, Linlin Nie, Shun Bai, Mingyu Guan, Xuke Li, Changchung Cheng
  • Patent number: 9802949
    Abstract: Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X?, Y, Y?, A, A?, Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: October 31, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Jiancun Zhang, Hongming Xie, Qingyun Ren, Shifeng Li, Changping Fu, Bailin Hu, Xiwei Wu, Changhua Tang
  • Patent number: 9771358
    Abstract: Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: September 26, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Qingyun Ren, Xinchang Liu, Siegfried Goldmann
  • Publication number: 20170267634
    Abstract: The compounds of Formula (I) which can be used as CRTH2 receptor antagonists are provided. The compounds of Formula (I) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin D2 (PGD2) at the CRTH2 receptor.
    Type: Application
    Filed: September 11, 2015
    Publication date: September 21, 2017
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Tianzhu YU, Bing LIU, Xiangyu ZHANG, Shiguo ZHANG, Changchung CHENG, Jiancun ZHANG
  • Publication number: 20170247332
    Abstract: Provided herein are a quinolinone compound, pharmaceutical composition thereof, and use of the compound or the pharmaceutical composition in drug preparation, the drug being used to prevent, manage, treat or relieve diseases related to HIF and/or EPO of a patient, including anemia, vascular disease, myocardial ischemia, dysmetabolism, or for wound healing.
    Type: Application
    Filed: September 1, 2015
    Publication date: August 31, 2017
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Yinglin Zuo, Xiaojun WANG, Yingjun ZHANG, Liang WEN, Shoutao WU, Xiaofeng YUAN